Regenerex Pharma (RGPX) 10-K 24 Jun 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2019	May 15, 2019
Document And Entity Information
Entity Registrant Name	PEPTIDE TECHNOLOGIES, INC.
Entity Central Index Key	0001357878
Document Type	10-K
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Is Entity Emerging Growth Company?	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Public Float	$ 0
Entity Common Stock, Shares Outstanding		127,112,660
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018
Entity Shell Company	false
Entity File Number	000-53230

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Current Assets
Cash and cash equivalents	$ 88,546	$ 1,728
Prepaid expenses	9,070
Total Current Assets	97,616	1,728
Website, net of accumulated amortization of $7,993 and $2,659 as of March 31, 2019 and 2018, respectively	8,007	13,341
Total Assets	105,623	15,069
Current Liabilities
Accounts payable	38,348	37,870
Related-party advances	130,990	67,113
Accrued compensation	221,192	221,192
Other accrued liabilities	14,778	10,000
Total Current Liabilities	405,308	336,175
Note Payable	70,000
Total Liabilities	475,308	336,175
Stockholders' Deficit
Common stock: $0.001 par value; 675,000,000 shares authorized; 127,112,660 issued and outstanding as of March 31, 2019 and 2018	127,113	127,113
Additional paid-in capital	776,963	731,963
Accumulated deficit	(1,273,761)	(1,180,182)
Total Stockholders' Deficit	(369,685)	(321,106)
Total Liabilities and Stockholders' Deficit	$ 105,623	$ 15,069

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Statement of Financial Position [Abstract]
Accumulated Amortization, Website	$ 7,993	$ 2,659
Common stock par value	$ 0.001	$ 0.001
Common stock, shares authorized	675,000,000	675,000,000
Common stock, shares issued	127,112,660	127,112,660
Common stock, shares outstanding	127,112,660	127,112,660

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating Expenses
General and administrative, including stock-based compensation of $45,000 and $10,250 for the years ended March 31, 2019 and 2018, respectively	$ 91,734	$ 49,451
Total Operating Expenses	(91,734)	49,451
Operating Loss	(91,734)	(49,451)
Other Expense
Interest expense	(778)
Foreign currency loss	(1,067)	(220)
Net Loss	$ (93,579)	$ (49,671)
Basic and Diluted Loss per Common Share	$ 0	$ 0
Weighted Average Number of Common Shares Outstanding	127,112,660	137,652,220

Statements of Operations (Paren

Statements of Operations (Parenthetical) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Stock-based Compensation	$ 45,000	$ 45,000	$ 10,250

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash Flows From Operating Activities:
Net loss	$ (93,579)	$ (49,671)
Adjustments to reconcile net loss to cash flows used in operating activities
Depreciation	5,334	2,659
Stock-based compensation	45,000	10,250
Changes in operating assets and liabilities:
Prepaid expenses	(9,070)
Accounts payable and accrued liabilities	5,256	640
Net cash flows used for operating activities	(47,059)	(36,122)
Cash Flows From Investing Activities:
Website development		(16,000)
Net cash used for investing activities		(16,000)
Cash Flows From Financing Activities:
Related-party advances	63,877	53,850
Note payable	70,000
Net cash provided by financing activities	133,877	53,850
Change in cash and equivalents	86,818	1,728
Cash and cash equivalents, beginning of year	1,728
Cash and cash equivalents, end of year	88,546	1,728
Supplemental Cash Flow Information:
Income taxes
Interest

Statements of Stockholders' Def

Statements of Stockholders' Deficit - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Mar. 31, 2017	$ 127,113	$ 731,963	$ (1,180,182)	$ (321,106)
Balance (in Shares) at Mar. 31, 2017	156,062,660
Rescission of common stock	$ (39,200)	39,200
Rescission of common stock (in Shares)	(39,200,000)
Stock-based compensation	$ 10,250			10,250
Stock-based compensation (in Shares)	10,250,000
Net Loss			(49,671)	(49,671)
Balance at Mar. 31, 2018	$ 127,113	692,763	(1,130,511)	$ (321,106)
Balance (in Shares) at Mar. 31, 2018	127,112,660			127,112,660
Rescission of common stock (in Shares)				39,200,000
Stock-based compensation		45,000		$ 45,000
Stock-based compensation (in Shares)
Net Loss				(93,579)
Balance at Mar. 31, 2019	$ 127,113	$ 731,963	$ (1,273,761)	$ (369,685)
Balance (in Shares) at Mar. 31, 2019	127,112,660			127,112,660

Nature Of Operations

Nature Of Operations	12 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature Of Operations	NOTE 1 – NATURE OF OPERATIONS Peptide Technologies, Inc., (the “Company” or “Peptide”), was incorporated in the State of Nevada, United States of America, on November 18, 2005. The Company’s business is to develop and market skincare products. Its plan is to build a state-of-the-art online store with a direct marketing and sales funnel aimed at targeted channels, using internet, social media, and content marketing. The Company’s marketing approach uses vetted channels that encompass several steps to gauge performance data from marketing tests against other campaigns in real-time with the ability to modify content delivery to targeted consumers immediately. The Company will engage a team with proprietary algorithmic software to assist in making these marketing decisions. Management believes this will provide the Company a distinct advantage over other companies that outsource marketing and advertising efforts to third parties. The skincare space is well-suited for direct-to-consumer sales, and there are several channels that the Company will leverage to introduce its unique branding and creative advertising assets. Creating brand visibility, along with the back-end support to process orders, is one of the Company’s key strengths over smaller competitors in the space. In addition, the Company will create a brand that allows visibility and awareness to be molded organically, thereby increasing the brand’s value quickly. The Company has identified a cosmetic and skincare manufacturer and has agreed upon product formulations, the design and sourcing of packaging, and product costs. The Company does not intend to enter into a long-term master supply agreement with the manufacturer. Rather, orders will be placed through individual purchase orders as needed. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital to carry out its plan of operation and competition from existing consumer product companies. The majority of manufacturing, distribution, marketing, and sales operations will be outsourced. However, strategic planning and development will be performed internally by the Company. This includes, but is not limited to, developing our catalog of products, developing proprietary skincare formulations, pricing our products, deciding which markets to target, deciding which influencers to engage in marketing campaigns, developing sales channels such as our e-commerce sites, determining which marketing initiatives to pursue, and selecting strategic partners and suppliers to advance our business plan.

Going Concern

Going Concern	12 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 – GOING CONCERN These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations and had an accumulated deficit of $1,273,761 as of March 31, 2019. The Company also has excess liabilities over assets of $369,685. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures. These financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Use of Estimates These financial statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could ultimately differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with original maturities of three months or less. Revenue Recognition Revenue is recognized upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management assesses the business environment, the customer’s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue in the second quarter of the fiscal year 2020. Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the years ended March 31, 2019 and 2018 was $5,334 and $2,659, respectively. Impairment of Long-Lived Assets The long-lived assets held and used by the Company are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the carrying amount of any long-lived asset may be impaired, an evaluation of recoverability is performed. There were no impairment losses during the years ended March 31, 2019 and 2018. Share-Based Payments The Company recognizes the cost of employee share-based payment awards on a straight-line attribution basis over the requisite employee service period, net of estimated forfeitures. Determining the fair value of share-based awards at the measurement date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise and the associated volatility. Peptide Technologies estimates the fair value of options granted using the Black-Scholes valuation model. The expected life of the options used in this calculation is the period of time the options are expected to be outstanding. Expected stock price volatility is based on the historical volatility of Peptide Technologies’ stock for a period approximating the expected life, and the risk-free interest rate is based on the implied yield available on US Treasury zero-coupon issues approximating the expected life. Judgment is also required in estimating the amount of share-based awards that will be forfeited prior to vesting. The fair value of restricted stock awards is based on the par value of Peptide Technologies’ common stock on the date of grant. Income Taxes Certain income and expense items are accounted for differently for financial reporting and income tax purposes. Deferred income tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities, applying enacted statutory income tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. Basic and Diluted Income (Loss) Per Share Basic income (loss) per common share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed similar to basic income (loss) per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings per share is not shown for periods in which the Company incurs a loss because it would be anti-dilutive. Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value: · Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. · Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace. · Level 3 - Unobservable inputs which are supported by little or no market activity. The Company’s financial instruments include accounts payable and accrued compensation. The carrying value of these instruments approximate their fair value because of their short-term nature. Foreign Currency Translation and Transactions The financial statements are presented in U.S. dollars. Foreign-denominated monetary assets and liabilities are translated to their U.S. dollar equivalents using foreign exchange rates at the balance sheet date. Revenue and expenses are translated at average rates of exchange during the period. Related translation adjustments are reported as a separate component of stockholders’ equity, whereas gains or losses resulting from foreign currency transactions are included in the results of operations. Recent Accounting Pronouncements The Financial Accounting Standards Board issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

Accrued Compensation

Accrued Compensation	12 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
Accrued Compensation	NOTE 4 – ACCRUED COMPENSATION Accrued compensation consists of the following: March 31, 2019 March 31, 2018 Salaries and benefits payable $ 212,000 $ 212,000 Payroll taxes payable 9,192 9,192 Total accrued compensation $ 221,192 $ 221,192

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2018
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 5 – RELATED PARTY TRANSACTIONS The Company’s former Chief Financial Officer (“CFO”) advanced $63,877 and $53,850 to the Company during the years ended March 31, 2019 and 2018, respectively, to pay for operating expenses. The advances are due on demand and carry no interest. The related-party advances totaled $130,990 and $67,113 as of March 31, 2019 and 2018, respectively.

Notes Payable

Notes Payable	12 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	NOTE 6 – NOTE PAYABLE During the year ended March 31, 2019, Black Star Holdings Ltd., a shareholder of the Company, was issued a promissory note in the principal amount of $70,000. The note is unsecured and bears interest at 10 percent, per annum. Repayment of this note is due no later than February 19, 2021. On April 15, 2019, Black Star Holdings Ltd. was issued an additional promissory note in the principal amount of $67,257 ($90,000 Canadian Funds). The note is unsecured and bears interest at 10 percent, per annum. Repayment of the note is due no later than April 15, 2021.

Common Stock

Common Stock	12 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Common Stock	NOTE 7 – COMMON STOCK The Company has authorized the issuance of 675,000,000 shares of common stock with a par value of $0.001 per share. 127,112,660 shares of common stock were issued and outstanding as of March 31, 2019 and 2018, respectively. The Company determined that the fair value of its common stock was equal to its par value during the years ended March 31, 2019 and 2018. During the year ended March 31, 2018, the Company’s Board of Directors approved the rescission of 39,200,000 shares of common stock. Prior to the Company’s change in business focus, these shares were issued, but not tendered, pending financial compensation to be received by the Company, agreements to be signed between the Company and certain consultants/shareholders, or specific performance by the consultants/shareholders. As these conditions were ultimately not met by these shareholders, the Board of Directors rescinded these shares. No value was ascribed to the shares cancelled, thus no gain was recorded. The Company’s Board of Directors and shareholders have agreed to indemnify the Company for any shareholder actions related to these share rescissions. In March 2018, the Company issued 5,000,000 shares of common stock with a fair value of $5,000 to Byron Striloff in connection with his appointment as President of the Company. The Company also issued 5,000,000 shares of common stock with a fair value of $5,000 to Bruce Sellars in connection with his appointment as a Director and Chief Executive Officer of the Company. Additionally, the Company issued 250,000 shares of common stock with a fair value of $250 to Irene Getty in connection with her appointment to the Board of Directors. In December 2018, Baxter Koehn, who was the Chairman of the Board of Directors and Chief Financial Officer, transferred 45,000,000 shares of common stock with an estimated fair value of $45,000 to Irene Getty upon her appointment as the new Chief Financial Officer and his resignation from the Board of Directors. As Mr. Koehn was a significant shareholder owning more than 10% of the shares outstanding at the time, the Company recognized stock-based compensation expense of $45,000 related to this transfer of shares based on management’s estimate of the fair value of the entity, net of liabilities. The stock-based compensation was recorded within general and administrative expense on the accompanying statement of operations.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 8 – INCOME TAXES The 2017 Tax Act, which was signed into law on December 22, 2017, has resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from the maximum rate of 35% to 21%, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system and includes base erosion prevention measures on non-U.S. earnings, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low taxed income (GILTI). These changes were effective beginning in 2018. Income tax expense differs from the amount that would result from applying the federal income tax rate to earnings before income taxes. Reconciliations of the U.S. federal statutory rate to the actual tax rate are as follows for the years ended March 31, 2019 and 2018: 2019 2018 Federal tax benefit at statutory rate 21.0 % 35.0 % Permanent differences: Stock compensation -10.1 % -7.2 % Temporary differences: Accounts payable and accrued liabilities -0.1 % -0.5 % Other -0.1 % -1.2 % Change in valuation allowance -10.7 % 294.3 % Change in effective tax rate 0.0 % -320.4 % Total provision 0.0 % 0.0 % The composition of the Company’s deferred tax assets as of March 31, 2019 and 2018 is as follows: Asset (Liability) 2019 2018 Other $ 10,000 $ 8,000 Net operating loss carryforwards 239,000 231,000 Valuation allowance (249,000 ) (239,000 ) Net deferred tax asset $ — $ — Due to the reduction in the federal statutory rate resulting from the Tax Act, deferred tax assets decreased by $160,000, and the valuation allowance decreased by $160,000 during the year ended March 31, 2018. The valuation allowance increased by $10,000 during the year ended March 31, 2019. The Company had a net operating loss carryforward balance of $1,148,764 and $1,100,663 as of March 31, 2019 and 2018, respectively. The Company’s net operating losses have expiration dates ranging from 2024 to 2038. The Company’s recognized and unrecognized deferred tax assets related to unused tax losses. A full valuation allowance has been recorded against the potential deferred tax assets associated with all the loss carryforwards as their utilization is not considered “more likely than not” at this time.

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	NOTE 9 – COMMITMENTS AND CONTINGENCIES The Company is not currently involved with and does not have knowledge of any pending or threatened litigation against the Company or any of its officers.

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 – SUBSEQUENT EVENTS See Note 6.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates These financial statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could ultimately differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with original maturities of three months or less.
Revenue Recognition	Revenue Recognition Revenue is recognized upon shipment or upon receipt of products by the customer, depending on the agreed-upon terms, provided that: there are no uncertainties regarding customer acceptance; persuasive evidence of an agreement exists documenting the specific terms of the transaction; the sales price is fixed or determinable; and collectability is reasonably assured. Management assesses the business environment, the customer’s financial condition, historical collection experience, accounts receivable aging, and customer disputes to determine whether collectability is reasonably assured. If collectability is not considered reasonably assured at the time of sale, the Company does not recognize revenue until collection occurs. The Company plans to begin recognizing revenue in the second quarter of the fiscal year 2020.
Website	Website Expenditures related to the planning and operation of the Company’s website are expensed as incurred. Expenditures related to the website application and infrastructure development are capitalized and amortized over the website’s estimated useful life of three (3) years. Amortization expense for the years ended March 31, 2019 and 2018 was $5,334 and $2,659, respectively.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The long-lived assets held and used by the Company are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the carrying amount of any long-lived asset may be impaired, an evaluation of recoverability is performed. There were no impairment losses during the years ended March 31, 2019 and 2018.
Share-Based Payments	Share-Based Payments The Company recognizes the cost of employee share-based payment awards on a straight-line attribution basis over the requisite employee service period, net of estimated forfeitures. Determining the fair value of share-based awards at the measurement date requires judgment, including estimating the expected term that stock options will be outstanding prior to exercise and the associated volatility. Peptide Technologies estimates the fair value of options granted using the Black-Scholes valuation model. The expected life of the options used in this calculation is the period of time the options are expected to be outstanding. Expected stock price volatility is based on the historical volatility of Peptide Technologies’ stock for a period approximating the expected life, and the risk-free interest rate is based on the implied yield available on US Treasury zero-coupon issues approximating the expected life. Judgment is also required in estimating the amount of share-based awards that will be forfeited prior to vesting. The fair value of restricted stock awards is based on the par value of Peptide Technologies’ common stock on the date of grant.
Income Taxes	Income Taxes Certain income and expense items are accounted for differently for financial reporting and income tax purposes. Deferred income tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities, applying enacted statutory income tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.
Basic and Diluted Income (Loss) Per Share	Basic and Diluted Income (Loss) Per Share Basic income (loss) per common share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed similar to basic income (loss) per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings per share is not shown for periods in which the Company incurs a loss because it would be anti-dilutive.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants as of the measurement date. Applicable accounting guidance provides an established hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. There are three levels of inputs that may be used to measure fair value: · Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. · Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace. · Level 3 - Unobservable inputs which are supported by little or no market activity. The Company’s financial instruments include accounts payable and accrued compensation. The carrying value of these instruments approximate their fair value because of their short-term nature.
Foreign Currency Translation and Transactions	Foreign Currency Translation and Transactions The financial statements are presented in U.S. dollars. Foreign-denominated monetary assets and liabilities are translated to their U.S. dollar equivalents using foreign exchange rates at the balance sheet date. Revenue and expenses are translated at average rates of exchange during the period. Related translation adjustments are reported as a separate component of stockholders’ equity, whereas gains or losses resulting from foreign currency transactions are included in the results of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Financial Accounting Standards Board issues Accounting Standards Updates (“ASU”) to amend the authoritative literature in the Accounting Standards Codification (“ASC”). There have been a number of ASUs to date that amend the original text of the ASC. The Company believes those updates issued-to-date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company.

Accrued Compensation (Tables)

Accrued Compensation (Tables)	12 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
Schedule of Accounts Payable And Accrued Liabilities	March 31, 2019 March 31, 2018 Salaries and benefits payable $ 212,000 $ 212,000 Payroll taxes payable 9,192 9,192 Total accrued compensation $ 221,192 $ 221,192

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Reconciliation Of The Income Tax Provision	2019 2018 Federal tax benefit at statutory rate 21.0 % 35.0 % Permanent differences: Stock compensation -10.1 % -7.2 % Temporary differences: Accounts payable and accrued liabilities -0.1 % -0.5 % Other -0.1 % -1.2 % Change in valuation allowance -10.7 % 294.3 % Change in effective tax rate 0.0 % -320.4 % Total provision 0.0 % 0.0 %
Deferred Income Tax Assets And Liabilities	Asset (Liability) 2019 2018 Other $ 10,000 $ 8,000 Net operating loss carryforwards 239,000 231,000 Valuation allowance (249,000 ) (239,000 ) Net deferred tax asset $ — $ —

Accrued Compensation (Detail) -

Accrued Compensation (Detail) - Schedule of Accounts Payable And Accrued Liabilities - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Payables and Accruals [Abstract]
Salaries and benefits payable	$ 212,000	$ 212,000
Payroll taxes payable	9,192	9,192
Accrued compensation	$ 221,192	$ 221,192

Income Taxes (Detail) - Reconci

Income Taxes (Detail) - Reconciliation Of The Income Tax Provision	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Federal tax benefit at statutory rate	2100.00%	3500.00%
Permanent differences:
Stock compensation	(1010.00%)	(720.00%)
Temporary differences:
Accounts payable and accrued liabilities	(10.00%)	(50.00%)
Other	(10.00%)	(120.00%)
Change in valuation allowance	(1070.00%)	29430.00%
Change in effective tax rate	0.00%	(32040.00%)
Total provision	0.00%	0.00%

Income Taxes (Detail) - Deferre

Income Taxes (Detail) - Deferred Income Tax Assets And Liabilities - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Current:
Other	$ 10,000	$ 8,000
Noncurrent:
Net operating loss carryforwards	239,000	231,000
Valuation allowance	(249,000)	(239,000)
Net deferred tax asset

Nature Of Operations (Details N

Nature Of Operations (Details Narrative)	12 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Date of Incorporation	Nov. 18, 2005

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 1,273,761	$ 1,180,182
Total Stockholders' Deficit	$ 369,685	$ 321,106	$ 321,106

Significant Accounting Polici_3

Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Accounting Policies [Abstract]
Website Estimated Useful Life	3 years
Website Expenses Amortization	$ 5,334	$ 2,659
Impairment Losses

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Related party advances	$ 130,990	$ 67,113
Chief Executive Officer [Member]
Related party advances	$ 63,877	$ 53,850

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - Black Star Holdings Ltd. [Member] - USD ($)	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2019
Promissory Note 1 [Member]
Note Amount	$ 70,000
Note Interest Rate	10.00%
Note Repayment Date	Feb. 19, 2021
April 15, 2019 Promissory Note [Member]
Note Amount		$ 67,257
Note Interest Rate		10.00%
Note Repayment Date	Apr. 15, 2021

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Dec. 31, 2018	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Common stock par value		$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized		675,000,000	675,000,000	675,000,000
Common stock, shares issued		127,112,660	127,112,660	127,112,660
Common stock, shares outstanding		127,112,660	127,112,660	127,112,660
Rescission of common stock (in Shares)			39,200,000
Shares Transferred	$ 45,000,000
Shares Transferred, Fair Value	45,000
Stock-based compensation	$ 45,000		$ 45,000	$ 10,250
President [Member]
Stock Issued in Period		5,000,000
Stock Issued in Period (Fair Value)		$ 5,000
Chief Executive Officer [Member]
Stock Issued in Period		5,000,000
Stock Issued in Period (Fair Value)		$ 5,000
Director [Member]
Stock Issued in Period		250,000
Stock Issued in Period (Fair Value)		$ 250

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Non-current Deferred Tax Assets (Decreased)		$ (160,000)
Valuation Allowance (Increase/Decreased)	$ 10,000	(160,000)
Net Operating Loss Carryforward	$ 1,148,764	$ 1,100,663
Minimum [Member]
Net Operating Losses Expiration Dates	Mar. 31, 2024
Maximum [Member]
Net Operating Losses Expiration Dates	Mar. 31, 2038